Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...
(Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate ...
From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...
Democratic Party leaders and their donors bear responsibility for the increasingly widespread view of trans rights as ...
Trump’s newly named WH chief of staff Susie Wiles retained her position as co-chair of the lobbying firm Mercury Public ...
Hosted on MSN6d
Gilead Sciences Earnings Transcript (NASDAQ:GILD)Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca ... the market is primarily white MSMs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback